Consistent with our findings, higher expression of CD46 has been observed in ovarian cancer, breast cancer, prostate cancer, bladder cancer, and colon cancer tissue vs. adjacent normal tissues (13, 17–21), and the levels of sCD46 have also been reported to be increased (22). Here, CD46 is linked to urinary bladder carcinoma.